Frank Mubiru1, Barbara Castelnuovo1, Steven J Reynolds2,3, Agnes Kiragga1, Harriet Tibakabikoba1, Noela Clara Owarwo1, Andrew Kambugu1, Mohammed Lamorde1, Rosalind Parkes-Ratanshi1,4. 1. Infectious Disease Institute, Makerere University, Kampala, Uganda. 2. Division of Intramural Research, National Institute of Allergy and Infectious Diseases, National Institutes of Health, Bethesda, Maryland, United States of America. 3. Johns Hopkins University School of Medicine, Baltimore, Maryland, United States of America. 4. University of Cambridge, Institute of Public Health, Forvie Site, Cambridge, United kingdom.
Abstract
INTRODUCTION: Cardiovascular disease (CVD) is the leading cause of death globally, representing 31% of all global deaths. HIV and long term anti-retroviral therapy (ART) are risk factors for development of CVD in populations of people living with HIV (PLHIV). CVD risk assessment tools are currently being applied to SSA populations, but there are questions about accuracy as well as implementation challenges of these tools in lower resource setting populations. We aimed to assess the level of agreement between the various cardiovascular screening tools (Data collection on Adverse effects of anti-HIV Drugs (D:A:D), Framingham risk score, WHO risk score and The Atherosclerotic Cardiovascular Disease Score) when applied to an HIV ART experienced population in Sub-Saharan Africa. METHODS: This study was undertaken in an Anti-Retroviral Long Term (ALT) Cohort of 1000 PLHIV in care who have been on ART for at least 10 years in urban Uganda. A systematic review was undertaken to find the most frequently used screening tools from SSA PLHIV populations; these were applied to the ALT cohort. Levels of agreement between the resulting scores (those including lipids and non-lipids based, as well as HIV-specific and non-HIV specific) as applied to our cohort were compared. Prevalence Bias Adjusted Kappa was used to evaluate agreement between tools. RESULTS: Overall, PLHIV in ALT cohort had a median score of 1.1-1.4% risk of a CVD event over 5 years and 1.7-2.5% risk of a CVD event over 10 years. There was no statistical difference in the risk scores obtained for this population when comparing the different tools, including comparisons of those with lipids and non-lipids, and HIV specific vs non-HIV specific. CONCLUSION: The various tools yielded similar results, but those not including lipids are more feasible to apply in our setting. Long-term cohorts of PLHIV in SSA should in future provide longitudinal data to evaluate existing CVD risk prediction tools for these populations. Inclusion of HIV and ART history factors to existing scoring systems may improve accuracy without adding the expense and technical difficulty of lipid testing.
INTRODUCTION:Cardiovascular disease (CVD) is the leading cause of death globally, representing 31% of all global deaths. HIV and long term anti-retroviral therapy (ART) are risk factors for development of CVD in populations of people living with HIV (PLHIV). CVD risk assessment tools are currently being applied to SSA populations, but there are questions about accuracy as well as implementation challenges of these tools in lower resource setting populations. We aimed to assess the level of agreement between the various cardiovascular screening tools (Data collection on Adverse effects of anti-HIV Drugs (D:A:D), Framingham risk score, WHO risk score and The Atherosclerotic Cardiovascular Disease Score) when applied to an HIV ART experienced population in Sub-Saharan Africa. METHODS: This study was undertaken in an Anti-Retroviral Long Term (ALT) Cohort of 1000 PLHIV in care who have been on ART for at least 10 years in urban Uganda. A systematic review was undertaken to find the most frequently used screening tools from SSA PLHIV populations; these were applied to the ALT cohort. Levels of agreement between the resulting scores (those including lipids and non-lipids based, as well as HIV-specific and non-HIV specific) as applied to our cohort were compared. Prevalence Bias Adjusted Kappa was used to evaluate agreement between tools. RESULTS: Overall, PLHIV in ALT cohort had a median score of 1.1-1.4% risk of a CVD event over 5 years and 1.7-2.5% risk of a CVD event over 10 years. There was no statistical difference in the risk scores obtained for this population when comparing the different tools, including comparisons of those with lipids and non-lipids, and HIV specific vs non-HIV specific. CONCLUSION: The various tools yielded similar results, but those not including lipids are more feasible to apply in our setting. Long-term cohorts of PLHIV in SSA should in future provide longitudinal data to evaluate existing CVD risk prediction tools for these populations. Inclusion of HIV and ART history factors to existing scoring systems may improve accuracy without adding the expense and technical difficulty of lipid testing.
Authors: Daniel Muyanja; Conrad Muzoora; Anthony Muyingo; Winnie Muyindike; Mark J Siedner Journal: AIDS Patient Care STDS Date: 2015-12-18 Impact factor: 5.078
Authors: Barbara Castelnuovo; Frank Mubiru; Agnes N Kiragga; Rachel Musomba; Olive Mbabazi; Paul Gonza; Andrew Kambugu; Rosalind Parks Ratanshi Journal: BMJ Open Date: 2018-02-21 Impact factor: 2.692
Authors: Steve Raoul Noumegni; Jean Joel Bigna; Vicky Jocelyne Ama Moor Epse Nkegoum; Jobert Richie Nansseu; Felix K Assah; Ahmadou Musa Jingi; Magellan Guewo-Fokeng; Steve Leumi; Jean-Claude Katte; Mesmin Y Dehayem; Liliane Mfeukeu Kuate; Andre Pascal Kengne; Eugene Sobngwi Journal: BMJ Open Date: 2017-08-11 Impact factor: 2.692
Authors: Barbara Castelnuovo; Agnes Kiragga; Victor Afayo; Malisa Ncube; Richard Orama; Stephen Magero; Peter Okwi; Yukari C Manabe; Andrew Kambugu Journal: PLoS One Date: 2012-12-17 Impact factor: 3.240
Authors: Max Weyler Nery; Celina Maria Turchi Martelli; Erika Aparecida Silveira; Clarissa Alencar de Sousa; Marianne de Oliveira Falco; Aline de Cássia Oliveira de Castro; Jorge Tannus Esper; Luis Carlos Silva e Souza; Marília Dalva Turchi Journal: ScientificWorldJournal Date: 2013-10-21
Authors: Titus Msoka; Josephine Rogath; Gary Van Guilder; Gibson Kapanda; Yvo Smulders; Marceline Tutu van Furth; John Bartlett; Michiel van Agtmael Journal: HIV AIDS (Auckl) Date: 2021-06-03